NASHVILLE, TENN., June 2, 2022 – Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place in Chicago and online from June 3-7, 2022. Experts from across Sarah Cannon Research Institute’s network will join oncology leaders from around the globe to discuss the latest research findings that are accelerating progress in the fight against cancer. As a leader in drug development, Sarah Cannon Research Institute is presenting data from 75 early-phase studies.
“Collaboration is essential to how we accelerate progress in the fight against cancer, and we look forward to coming together with our colleagues in Chicago to discuss the latest advances in oncology research,” said Howard A. “Skip” Burris III, MD, FACP, FACSO, President, Clinical Operations & Chief Medical Officer, Sarah Cannon Research Institute. “With the variety of novel molecularly-targeted agents, immunotherapies, and cellular therapies in development, we are seeing a remarkable number of possibilities to truly transform care and personalize treatments for patients.”
Presentations will cover a wide range of topics including how targeted agents and immunotherapies are performing in an array of disease settings, how molecular profiling is expanding access to clinical trials, and how researchers are advancing clinical research despite pressures in a post-pandemic environment.
Below are several highlighted presentations that Sarah Cannon principal investigators will lead during the Annual Meeting:
- Gerald Falchook, MD, MS, Director, Drug Development, Sarah Cannon Research Institute at HealthONE, will deliver “Phase 1 Trial of TIM-3 Inhibitor Cobolimab Monotherapy and in Combination with PD-1 Inhibitors Nivolumab or Dostarlimab (AMBER)” in an oral presentation on June 4 from 1:15-4:15 p.m. CDT (2:27 p.m. CDT) in Hall B1.
- Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, will give two oral presentations – “Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (pts) with HER2-Positive (HER2+) Unresectable and/or Metastatic Breast Cancer (mBC): Safety Follow-Up of the Randomized, Phase 3 Study DESTINY-Breast03” on June 4 from 1:15-4:15 p.m. CDT (1:15 p.m. CDT) in Hall D1 and “Phase I, Two-Part, Multicenter, First-In-Human (FIH) Study of DS-6000a in Subjects with Advanced Renal Cell Carcinoma (RCC) and Ovarian Tumors (OVC)” on June 7 from 9:45 a.m. – 12:45 p.m. CDT (10:09 a.m. CDT) in S406.
- Melissa Johnson, MD, Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology, will present “Resistance to KRAS Inhibition and Future Combinations” in the Education Session, Development of Novel Inhibitors of the RAS Pathway, on June 7 from 8-9:15 a.m. CDT in S406. Dr. Johnson will also present “Dose Escalation of a Phase 1b/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (pts) with Metastatic Solid Tumors” in an oral presentation on June 4 from 1:15-4:15 p.m. CDT (1:51 p.m. CDT) in Hall B1.
- Andrew McKenzie, PhD, Vice President, Personalized Medicine, Sarah Cannon Research Institute; Scientific Director, Genospace, will present “Expanding Access to Clinical Trials Through Molecular Profiling Review and Telehealth Consultations” during the Education Session, Rethinking Cancer Clinical Trial Conduct With Telemedicine, on June 6 from 4:45-6 p.m. CDT in S504.
- Jeremy Pantin, MD, Senior Investigator, Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial, will chair the Clinical Science Symposium, Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies, as well as discuss "Refining the CAR-T's Engine: How to Improve CD19-Directed CAR-T Performance” on June 6 from 8-9:30 a.m. CDT in S100bc.
- David Spigel, MD, Chief Scientific Officer, Sarah Cannon Research Institute, is a speaker and panelist on the Education Session, The Business of Clinical Trials: The Impact of Funds Flow and the Shrinking Workforce on Trial Development, on June 5 from 8-9:15 a.m. CDT in S102.
Abstracts and presentations with Sarah Cannon experts as first authors will be presented by:
- Dr. Howard Burris
- Dr. Gerald Falchook
- Lucio Gordan, MD, Chief Medical Officer, Sarah Cannon Research Institute at Florida Cancer Specialists
- Dr. Erika Hamilton
- Marilyn (Holt) Hammer, PhD, Program Specialist, Personalized Medicine, Sarah Cannon Research Institute
- Lowell Hart, MD, FACP, Scientific Director, Clinical Research, Sarah Cannon Research Institute at Florida Cancer Specialists
- Shekeab Jauhari, MD, Associate Director, Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Mary
- Dr. Melissa Johnson
- William Kevin Kelly, DO, Senior Investigator, Drug Development, Sarah Cannon Research Institute at Sidney Kimmel Cancer Center
- Meredith McKean, MD, MPH, Director, Melanoma & Skin Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology
- Dr. Andrew McKenzie (Chair)
- Kathleen Moore, MD, Director, Drug Development, Sarah Cannon Research Institute at the Stephenson Cancer Center
- Manish Patel, MD, Director, Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists – Sarasota
- Meredith Pelster, MD, MSCI, Assistant Director, Gastrointestinal Research, Sarah Cannon Research Institute at Tennessee Oncology
- Cesar Augusto Perez, MD, Director, Drug Development, Sarah Cannon Research Institute at Florida Cancer Specialists – Lake Nona
- Russell Schilder, MD, Director, Drug Development, Sarah Cannon Research Institute at Sidney Kimmel Cancer Center
- Emma Sturgill, PhD, Senior Program Specialist, Personalized Medicine, Sarah Cannon Research Institute
- Susanna Ulahannan, MD, MMed, Associate Director, Phase 1 Program, Sarah Cannon Research Institute at The Stephenson Cancer Center (Co-Chair)
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US. Please click here to earn more about our research offerings.
About Our Network of Strategic Sites
Hematology/Oncology Clinic, Messino Cancer Centers, Sarah Cannon Research Institute at Florida Cancer Specialists, Sarah Cannon Research Institute at HCA Midwest Health, Sarah Cannon Research Institute at HealthONE, Sarah Cannon Research Institute at Tennessee Oncology, Sarah Cannon Research Institute - United Kingdom, Sidney Kimmel Cancer Center at Jefferson Health, The Stephenson Cancer Center at the University of Oklahoma, Zangmeister Cancer Center.